P71 Tamoxifen–Norfloxacin interaction induced Q-T interval prolongation in an older female patient with extracranial meningioma: a case report

Slováček, Ladislav; Priester, Peter; Slánská, Iva; Petera, Jiřı́

doi:10.1016/s1040-8428(09)70109-x

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data on any other medications administered during the trial was unavailable. 13 Slovacek et al 14,15 published two case reports out of the Czech Republic linking tamoxifen and QT prolongation. The first case report involved a 56-year-old female patient with estrogen/progesterone receptorpositive, HER-2-negative breast cancer.…”

Section: Literature Reviewmentioning

confidence: 99%

“…14 The second case report by Slovacek et al involved an 83-year-old female patient being treated with tamoxifen 20 mg daily for an extracranial meningioma. 15 At the time of tamoxifen treatment, the patient was also completing a seven-day course of norfloxacin 400 mg twice daily for a urinary tract infection. After three days of using the two medications concurrently, the patient developed pressure behind her sternum and orthostatic hypotension.…”

Section: Literature Reviewmentioning

confidence: 99%

“…She remained on tamoxifen with no further incident. 15 Finally, Chiu et al 16 published a case report which involved a 78-year-old female with a history of breast cancer and moderate chronic obstructive pulmonary disease (COPD), who presented to the emergency department. The patient's medical history included invasive ductal carcinoma of the breast for which she underwent a total mastectomy and had been on tamoxifen 20 mg daily for nine months.…”

Section: Literature Reviewmentioning

confidence: 99%

See 2 more Smart Citations

The clinical significance of QT prolongation associated with tamoxifen: A review of the literature

Fung

Imeson

Cusano

2017

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective To review the literature discussing QT prolongation associated with the use of tamoxifen in order to evaluate the clinical significance. Data sources A search of PubMed (1946 to 2017), MEDLINE (1946 to 2017) and EMBASE (1947 to 2017) was performed using a combination of the following search terms: tamoxifen, estrogen antagonist, selective estrogen receptor modulator, QT prolongation, QT interval, long QT syndrome and torsades de pointes. All searches were limited to human subjects. Reference lists of the literature found were also reviewed but did not reveal any further articles. Study selection Articles reviewed were relating to humans only and included clinical trials and case reports that mentioned QT prolongation in association with the use of tamoxifen. Data synthesis It can be common for patients on tamoxifen to also be on a number of different medications being used to treat comorbid medical conditions. Such combinations of medications increase the potential risk for drug interactions, such as drug-induced QT prolongation. Tamoxifen is often flagged by tertiary drug information sources as a drug with indeterminate effects on the QT interval. However, the risk may be elevated when combined with other QT-prolonging agents. A total of five publications were identified, including two phase I clinical trials and three case reports, which discussed the association between tamoxifen and QT prolongation. Conclusions Tertiary drug information sources identify tamoxifen as an agent that may cause QT prolongation when used in combination with other QT-prolonging agents. However, based on the limited number of published reports found, it would suggest that the use of tamoxifen concurrently with other agents known to prolong the QT interval is likely to be of low risk for causing a clinically significant QT-prolonging event, especially at a dose of 20 mg daily.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Section: Literature Reviewmentioning

confidence: 99%

Section: Literature Reviewmentioning

confidence: 99%

See 1 more Smart Citation

The clinical significance of QT prolongation associated with tamoxifen: A review of the literature

Fung

Imeson

Cusano

2017

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…A number of studies report a direct link between the use of QT-prolonging drugs and an increased risk of sudden cardiac [6,7] or cardiovascular death [8]. Moreover, there is evidence that the concomitant administration of more than one QT-prolonging drug may further increase the risk of developing a QT interval prolongation and TdP [9][10][11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recently, a large retrospective study found that a 5‐day course of the QT‐prolonging drug azithromycin increased risk of cardiovascular death by nearly threefold . Further, the concomitant administration of two or more QT‐prolonging medications may confer additive risk for QT interval prolongation and progression to TdP, based on growing evidence from case reports and in vitro studies . With rising polypharmacy in the USA, increasing numbers of patients may be exposed to this potential adverse event …”

Section: Introductionmentioning

confidence: 99%

Use of QT‐prolonging medications in US emergency departments, 1995–2009

Tay

Ewald

Bourgeois

2013

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

P71 Tamoxifen–Norfloxacin interaction induced Q-T interval prolongation in an older female patient with extracranial meningioma: a case report

Cited by 4 publications

References 0 publications

The clinical significance of QT prolongation associated with tamoxifen: A review of the literature

The clinical significance of QT prolongation associated with tamoxifen: A review of the literature

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

Use of QT‐prolonging medications in US emergency departments, 1995–2009

Contact Info

Product

Resources

About